MyelofludateNCT03832127
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
At risk: Primary completion moved at least 4 years 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Sep 7, 2029 Show 5 more changesShow less
- Eligibility criteria expanded, about 15 words
- Trial status changed: Unknown → Recruiting
- Start date moved earlier from Sep 9, 2022 to Sep 7, 2022
- Secondary endpoints: details revised at 4 of 6 entries
- Site details revised at 1 of 7 sites
- Minor Changed Registry marked status Unknown; last known: Recruiting
Notable Start date changed from estimate of Apr 1, 2022 to Sep 9, 2022v5 Show 4 more changesShow less
- Trial status: Not Yet Recruiting to Unknown
- Primary completion date: Apr 1, 2024 to Sep 9, 2024
- Study completion date: Apr 1, 2026 to Sep 9, 2026
- Site details revised at 7 of 7 sites
- Notable Primary completion date: Apr 1, 2022 to Apr 1, 2024
- Start date: Apr 1, 2019 to Apr 1, 2022
- Study completion date: Apr 1, 2024 to Apr 1, 2026
- Notable Eligibility criteria expanded, about 19 words
- Secondary endpoints: details revised at 1 of 6 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Detection of sensitivity of the lesions (osseous and extra-osseous) of 18Fludarabine PET (FludaTEP)
Timeframe: Before treatment
Secondary (6)
To evaluate the specificity and the positive and negative predictive values of the FludaTEP for the initial assessment through an optimal reading mode.
To evaluate the sensitivity, specificity, and positive and negative predictive values of the FludaTEP for the initial balance according to the local reading
To evaluate the prognostic impact of FDG-PET and FludaTEP on the number of lesions detected by each imaging technique in a population of MM patients in the 1st line therapeutic but not candidates for marrow autograft.
To evaluate the prognostic impact of FludaTEP on the initial assessment and for the end-of-treatment therapeutic evaluation
Evaluate in a population of MM patients the existence of a correlation between the 18Fludarabine and FDG uptake intensities
Show 1 moreShow less
Evaluate in a population of MM patients the existence of a correlation between the 18Fludarabine and FDG uptake intensities and the cytogenetic data Tolerance to 18F-Fludarabine
Arms and interventions
FludatepExperimental
PET with 18F-Fludarabine
Drugs: 18F-Fludarabine
Sites
7 sites in 1 country